Clinical trials: COPD Patients
Asthma, COPD
The Natural History of Small Airways Physiology in Diseased and Healthy States
Spirometry is a useful clinical tool for the assessment and monitoring of lung disease, however, it does not provide information on peripheral airways resistance.
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis
- Trial name
- NCT00677560
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COPD (Chronic Obstructive Pulmonary Disease)
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Primary Objective To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in…
- Trial name
- TRIVERSYTI (NCT03197818)
- Testing
- CHF 5993 100/6/12.5 µg, 160 µg budesonide + 4.5 µg formoterol fumarate
- Where
- 64 sites in China, South Korea and 1 more
- Volunteers
- 708 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
- Trial name
- NCT01332097
- Testing
- BCT197, Prednisone
- Where
- 6 sites in Bulgaria, Romania and 1 more
- Volunteers
- 183 people
- Sponsor
- Mereo BioPharma
Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Monitoring and Peer Support to Improve Treatment Adherence and Outcomes
The O2VERLAP study investigators would like to find out if individuals living with both COPD and OSA would benefit from an online, educational curriculum, coupled with access to peer support (i.e.
- Trial name
- O2VERLAP (NCT03446768)
- Testing
- Peer support, Online platform, Respiratory Therapist support
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- COPD Foundation
Atelectasis, Pulmonary Infection
Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery
The effect of biphasic positive airway pressure (Bi-PAP) at individualized pressures on the postoperative pulmonary recovery of morbidly obese patients (MOP) undergoing open bariatric surgery (OBS) and possible placebo…
- Conditions
- Atelectasis, Pulmonary Infection, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Disease
- Trial name
- NCT03438383
- Testing
- Bi-PAP
- Volunteers
- 48 people
- Sponsor
- Evangelismos Hospital
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate COPD-related clinical outcomes and total healthcare utilization in commercially insured (at least 40 years with a subanalysis of those aged 65 years and older) COPD population associated with the use of…
- Trial name
- NCT01331694
- Testing
- fluticasone/salmeterol combination (FSC) 250/50mcg, tiotropium, ipratropium bromide alone or in fixed dose combination with albuterol
- Volunteers
- 76,130 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg
The purpose of this study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011.
- Trial name
- NCT01762800
- Testing
- fluticasone propionate/salmeterol 50/250mcg, tiotropium bromide 18mcg, fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
- Where
- 39 sites in Japan
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the…
- Trial name
- NCT03964207
- Testing
- Tiotropium Respimat® (T1), Tiotropium Handihaler® (T2)
- Where
- 8 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Actuation Indicator Trial in Patients With COPD
The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD.
- Trial name
- NCT00928746
- Testing
- Ipratropium bromide
- Where
- 7 sites in United States
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD), Heart Failure
An Intervention to Improve Function in Severe Cardiopulmonary Illness
The study is a randomized trial of a cardiopulmonary self-management intervention to improve functional capacity, health-related quality of life, and to reduce health care utilization.
- Trial name
- NCT00467298
- Testing
- Exercise adherence, Self-management- prevention of illness, Self-management of illness
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA.
- Trial name
- Quercetin (NCT01708278)
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan
Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
The study will assess the long-term safety of the fixed combination product QVA149 versus placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe…
- Trial name
- NCT01610037
- Testing
- QVA149, Tiotropium
- Where
- 116 sites in Argentina, Colombia and 15 more
- Volunteers
- 1,215 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
- Trial name
- NCT01425801
- Testing
- LAS100977 0.313 μg, LAS100977 0.625 μg, LAS100977 1.25 μg
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- Trial name
- GLOW 1 (NCT01005901)
- Testing
- Glycopyrronium bromide
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 1,324 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
This study will evaluate the efficacy and safety data of AZD8871 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03645434
- Testing
- AZD8871, Anoro® Ellipta®
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Chronic Obstructive Pulmonary Disease (COPD)
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.
- Trial name
- MOVE-ON (NCT01232894)
- Testing
- Indacaterol, Long-acting beta2-agonist
- Where
- 8 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals